🇺🇸 FDA

Intelligence · Patents

Patents expiring in 2032

Annual patent cliff calendar for 2032 — US pharmaceutical patents by expiration date.

Patents
1,123

Quick answer

1,123 indexed pharmaceutical patents have expiration dates in 2032. Browse by soonest expiry with links to assignee companies and related drugs.

  1. US 8110209

    Intracutaneous injection

    XERIS PHARMACEUTICALS, INC. · Granted Tue Feb 07 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 02 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 8110651

    Multifunctional forms of polyoxazoline copolymers and drug compositions comprising the same

    Serina Therapeutics, Inc. · Granted Tue Feb 07 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 02 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 8110585

    Bicyclic compound and pharmaceutical use thereof

    Takeda Pharmaceutical Company Limited · Granted Tue Feb 07 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 02 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 8110674

    Therapeutic compositions

    Alnylam Pharmaceuticals, Inc. · Granted Tue Feb 07 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 02 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 8110553

    Methods and compositions for the treatment of gastrointestinal disorders

    IRONWOOD PHARMACEUTICALS, INC. · Granted Tue Feb 07 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 02 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 8110352

    Method of diagnosing and treating cancer using B-catenin splice variants

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Feb 07 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 02 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 8110594

    Diarylthiohydantoin compounds

    The Regents of the University of California · Granted Tue Feb 07 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 02 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 8114618

    Measuring circulating therapeutic antibody, antigen and antigen/antibody complexes using ELISA assays

    The Board of Regents of the University of Texas System · Granted Tue Feb 14 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 09 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 8114394

    Use of IL-1 antagonists to treat gout

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Feb 14 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 09 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 8114648

    In vivo incorporation of unnatural amino acids

    The Regents of the University of California · Granted Tue Feb 14 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 09 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 8114446

    Methods for modulating eicosanoid metabolism

    The Board of Regents of the University of Texas System · Granted Tue Feb 14 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 09 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 8114620

    Diagnostic and therapeutic target PRKX proteins for neurodegenerative diseases

    Takeda Pharmaceutical Company Limited · Granted Tue Feb 14 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 09 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 8114590

    Diagnosis and treatment of chronic lymphocytic leukemia (CLL)

    The Regents of the University of California · Granted Tue Feb 14 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 09 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 8114900

    Amorphous carvedilol dihydrogen phosphate

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Feb 14 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 09 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 8114830

    Polypeptoid pulmonary surfactants

    Northwestern University · Granted Tue Feb 14 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 09 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 8115011

    Diacylglycerol acyltransferase inhibitors

    Madrigal Pharmaceuticals, Inc. · Granted Tue Feb 14 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 09 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 8114835

    Self-assembling peptide amphiphiles for tissue engineering

    Northwestern University · Granted Tue Feb 14 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 09 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 8114848

    Immunomodulatory oligonucleotides

    The United States of America, as represented by the Department of Health and Human Services · Granted Tue Feb 14 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 09 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 8114843

    Photoreactive regulator of protein function and methods of use thereof

    The Regents of the University of California · Granted Tue Feb 14 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 09 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 8114851

    Method and medicament for inhibiting the expression of a given gene

    Alnylam Pharmaceuticals, Inc. · Granted Tue Feb 14 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 09 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 8114981

    Method and medicament for inhibiting the expression of a given gene

    Alnylam Pharmaceuticals, Inc. · Granted Tue Feb 14 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 09 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 8114406

    Peptides and their utility in modulation of behavior of cells expressing α3β1 integrins

    The United States of America as Represented by the Secretary of the Department of Health and Human Services · Granted Tue Feb 14 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 09 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 8114852

    N-linked glycosylation alteration in E1 glycoprotein of classical swine fever virus and novel classical swine fever virus vaccine

    The United States of America, as represented by the Secretary of Agriculture · Granted Tue Feb 14 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 09 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 8114984

    RNAi modulation of Aha and therapeutic uses thereof

    Alnylam Pharmaceuticals, Inc. · Granted Tue Feb 14 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 09 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 8114834

    Self-assembling peptide amphiphiles

    Northwestern University · Granted Tue Feb 14 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 09 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 8114390

    Method for treating hair growth disorders, such as female pattern alopecia, and compositions useful therefore

    Arizona Board of Regents on Behalf of the University of Arizona · Granted Tue Feb 14 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 09 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 8119796

    Biphenyl compounds useful as muscarinic receptor antagonists

    Theravance, Inc. · Granted Tue Feb 21 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 16 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 8119649

    Use of c-Src inhibitors alone or in combination with STI571 for the treatment of leukaemia

    The Board of Regents of the University of Texas System · Granted Tue Feb 21 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 16 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 8119769

    Complement depletion using recombinant human C-3 derivatives

    PLS-Design GmbH · Granted Tue Feb 21 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 16 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 8119631

    Inhibitors of interleukin-1β converting enzyme

    Vertex Pharmaceuticals Incorporated · Granted Tue Feb 21 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 16 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 8119398

    Adipose-derived stem cells for tissue regeneration and wound healing

    PrimeGen Biotech LLC · Granted Tue Feb 21 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 16 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 8119618

    Compositions and methods for the treatment of inflammatory diseases

    The Board of Regents of the University of Oklahoma · Granted Tue Feb 21 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 16 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 8119590

    Prevention and treatment of restenosis by local administration of drug

    Esperion Therapeutics, Inc. · Granted Tue Feb 21 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 16 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 8119642

    Structurally rigid dopamine D3 receptor selective ligands and process for making them

    The United States of America as Represented by the Secretary of the Department of Health and Human Services · Granted Tue Feb 21 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 16 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 8119660

    Small-molecule inhibitors of the androgen receptor

    The Regents of the University of California · Granted Tue Feb 21 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 16 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 8119634

    Dual-acting pyrazole antihypertensive agents

    Theravance, Inc. · Granted Tue Feb 21 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 16 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 8119608

    Method and medicament for inhibiting the expression of a given gene

    Alnylam Pharmaceuticals, Inc. · Granted Tue Feb 21 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 16 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 8119655

    Kinase inhibitors

    Takeda Pharmaceutical Company Limited · Granted Tue Feb 21 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 16 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 8119809

    AMPK-activating heterocycloalkyloxy(hetero)aryl carboxamide, sulfonamide and amine compounds and methods for using the same

    Rigel Pharmaceuticals, Inc. · Granted Tue Feb 21 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 16 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 8119779

    Phosphoramidate derivatives

    University College Cardiff Consultants Limited · Granted Tue Feb 21 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 16 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 8119772

    MART-1 T cell receptors

    The Regents of the University of California · Granted Tue Feb 21 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 16 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 8119827

    Compounds for treatment of cell proliferative diseases

    The Board of Regents of the University of Texas System · Granted Tue Feb 21 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 16 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 8119656

    Inhibitors of the influenza virus non-structural 1 protein

    The Board of Regents of the University of Texas System · Granted Tue Feb 21 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 16 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 8123541

    Electrical connector with expanded cover

    Hon Hai Precision Ind. Co., Ltd. · Granted Tue Feb 28 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 23 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 8124101

    Genetically engineered swine influenza virus and uses thereof

    The United States of America, as represented by the Secretary of Agriculture · Granted Tue Feb 28 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 23 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 8124058

    Artificial nail compositions and related methods

    Creative Nail Design Inc. · Granted Tue Feb 28 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 23 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 8124584

    Macrocyclic hepatitis C serine protease inhibitors

    Enanta Pharmaceuticals, Inc. · Granted Tue Feb 28 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 23 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 8124669

    Dental composition

    Kuraray Medical Inc. · Granted Tue Feb 28 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 23 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many pharma patents expire in 2032?

1,123 published patents in our USPTO index have expiration dates falling in calendar year 2032.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.